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Background: Hypertrophic cardiomyopathy (HCM) is known to cause sudden cardiac death (SCD) in a proportion of affected patients. The most 
effective treatment for primary prevention of SCD is the placement of an implantable cardioverter defibrillator (ICD), though no treatment guidelines 
were in place until recently. The difference and effectiveness of the new guidelines compared to previous accepted major risk criteria to detect high-
risk patients remains unknown.
Methods: We retrospectively studied 110 consecutive patients who were referred to our HCM Center. Patients were assessed for risk for SCD 
with both the previous accepted major risk criteria and the new ACCF/AHA HCM guidelines. We evaluated those patients who received an ICD and 
followed them for the incidence of appropriate therapy (antitachycardia pacing [ATP] or shock).
Results: The mean age of the patients was 56 years (range 19 to 88 years), and 61% were males. Thirty-eight patients received ICDs (35%) under 
both the old major risk criteria as well as the new ACCF/AHA guidelines. The indications were: sustained VT: 9 (Class I, 23.7%), family history of HCM 
related SCD: 20, recurrent unexplained syncope: 11, wall thickness ≥ 30mm: 12, and non sustained VT with other risk factors: 5 (Class IIa, 63.1%). 
Five patients had ICDs for NSVT alone (Class IIb, 13.2%). Twenty-three patients had 1 risk factor with mean follow-up of 690 days, 12 had 2 risk 
factors with mean follow-up of 866 days, and 3 had 3 or more risk factors with mean follow-up of 1242 days. One patient had VT requiring ATP, no 
shocks were delivered for VT, and 4 patients received inappropriate shocks for supraventricular tachycardia and/or lead fracture. The patient with 
sustained VT requiring ATP had only 1 risk factor.
Conclusion: Among consecutive patients referred to a quarternary center for HCM care, 35% meet indications for ICD placement based on recently 
developed guidelines. However only one appropriate ICD therapy occurred (0.3%/year ), and was exceeded by the incidence of inappropriate events. 
Despite the development of new guidelines for management of HCM patients, there appears a need for a new risk assessment model to maximize 
the efficacy to safety ratio of ICD placement.
